TOLREMO therapeutics Company
TOLREMO has created ground-breaking scientific knowledge that allows it to pursue its passion to discover and develop novel targeted therapeutics that will meaningfully extend the lives of patients suffering from cancer.
TOLREMO therapeutics AG (“TOLREMO”) is a privately held research-stage biotechnology company. TOLREMO was founded in March 2017 as an ETH Spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin, and Emmanuel Savioz (MBA). The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug resistance therapies.
TOLREMO therapeutics AG (“TOLREMO”) is a privately held research-stage biotechnology company. TOLREMO was founded in March 2017 as an ETH Spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin, and Emmanuel Savioz (MBA). The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug resistance therapies.
Technology:
Precision Medicine
Industry:
P3 Medicine
Headquarters:
Zürich, Zurich, Switzerland
Founded Date:
2017
Employees Number:
1-10
Funding Status:
Early Stage Venture
Register and Claim Ownership